

Ref: EPL/CS/SE/0003/2026

Date: January 22, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Board Meeting intimation for approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that a meeting of the Board of Directors of the Company is scheduled to be held on **Wednesday, February 04, 2026** *inter-alia* to consider and approve the Unaudited Financial Results (Standalone And Consolidated) for the quarter and nine months ended December 31, 2025.

The trading window for dealing in securities of the Company by the Designated Persons and their relatives has been already closed from January 01, 2026, as communicated earlier vide our letter no. EPL/CS/SE/0098/2025 dated December 25, 2025 and shall remain closed till 48 hours after the declaration of the Unaudited Financial Results i.e. till February 06, 2026, in terms of the Company's Code of Conduct for regulating, monitoring and reporting of insider trading in the securities of the Company, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Tajuddin Shaikh
Chief Financial Officer

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251